Brolucizumab preserves vision in PDR

Proliferative diabetic retinopathy is the dangerous end of diabetic eye disease — the stage where the retina starts growing fragile new blood vessels that can bleed, scar, and pull vision apart. The old standard fix is panretinal photocoagulation, or PRP — basically a laser that burns parts of the peripheral retina to reduce the oxygen demand driving that abnormal vessel growth. It works, but the tradeoff has always been real: PRP can cost some peripheral and night vision, and it does not help the center of vision much if swelling shows up later. Now a big phase 3 trial says brolucizumab, an anti-VEGF eye injection, did better than PRP alone at preserving vision over 54 weeks in patients who had not yet been treated with laser. ### What is brolucizumab doing here? Brolucizumab is an anti-VEGF drug — it blocks the signal that tells those abnormal retinal blood vessels to keep growing and leaking. That makes it conceptually different from PRP. Laser changes the retina’s oxygen economics. Anti-VEGF turns down the growth signal directly. In the CONDOR trial, patients got three loading injections every 6 weeks, then maintenance every 12 weeks, with the option to stretch intervals later if disease stayed quiet. ### What was the actual study? CONDOR was a 96-week, randomized, single-masked phase 3 trial run at 152 sites across 16 countries. The published report covers the prespecified 54-week analysis. It enrolled 689 adults with type 1 or type 2 diabetes who had proliferative diabetic retinopathy in one study eye, had never had PRP in that eye, and did not have concurrent diabetic macular edema requiring treatment at baseline. Patients were split almost evenly — 347 to brolucizumab and 342 to PRP. ### How much better was vision? The main endpoint was change in best-corrected visual acuity at week 54. Brolucizumab was not just noninferior — it was superior. Mean vision was basically flat in the injection group, changing by 0.2 letters, while the PRP group lost 4.2 letters. That is a 4.4-letter advantage for brolucizumab. In plain English, the injection strategy did a better job holding central vision steady. ### Did it control the disease itself? Yes — and that may be the more important part. More eyes ended up with no active proliferative diabetic retinopathy, more eyes had a 2-step-or-greater improvement on diabetic retinopathy severity scoring, and fewer developed center-involved diabetic macular edema. That last point matters because macular edema is what often threatens the sharp72.7% for center-involved edema events, both favoring brolucizumab. ### So is laser now obsolete? Not really. This is the classic retina tradeoff. Injections can preserve vision better, but only if patients keep showing up. PRP is front-loaded — usually 1 to 4 sessions early on, then touch-ups as needed. That makes laser attractive for patients with shaky follow-up, transportation problems, cost barriers, or a history of missed visits. A treatment that works beautifully on paper can fail in real life if the schedule is too demanding. ### What is the catch on safety? Brolucizumab has baggage. After its launch in retinal disease, doctors became wary because of intraocular inflammation, including retinal vasculitis and retinal vascular occlusion in some patients. The CONDOR reporting says overall ocular adverse events were lower with brolucizumab than PRP, but inflammation-related events still need close attention. So this is not a casual swap. It is a stronger efficacy option with a specific safety concern attached. ### Why does this matter beyond one drug? Because it sharpens a broader shift in diabetic retinopathy care. Retina specialists have been moving from “laser first” toward anti-VEGF in selected patients for years, but the practical question has always been who can realistically stay on treatment. CONDOR gives that argument more weight. If a patient can adhere to injections and monitoring, a ## Bottom line This trial does not kill laser. But it does make the hierarchy clearer. For the right patient — reliable follow-up, close monitoring, tolerance for injections — brolucizumab looks better at keeping vision intact than PRP alone.